Action Alerts PLUS
Marvell Technology Is Likely to Stop Out Our Long Recommendation Friday
Let's review the charts.
Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
A Little Lower and Mondelez Looks Like a Sweet Opportunity
Eating up MDLZ on a dip toward $50 looks like a delicious move.
Play Defense, Palo Alto Networks Has Further to Fall
PANW's decline does not appear to be over.
Jim Cramer: Etsy Is Ridiculously Undervalued
The Brooklyn-based company has a worldwide opportunity to match rabid sellers with rabid buyers.
Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary
Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.
Kohl's Could Rally From Here but Needs to Prove Its Strength
The retailer's shares are rising after reporting earnings, but the mixed indicators found in its charts make it questionable whether the rally can be sustained.
I Do Not Expect Citigroup to Outperform the Market
Why Citigroup's underperformance versus the S&P 500 and the XLF will likely continue.
Cisco Could Rally to New Highs in the Next Few Months
Here's how traders and investors can play it.